Global Diabetes Treatment Devices Market By Device Type BGM Devices, Continuous Glucose Monitoring Devices, Insulin Delivery Devices, By End User (Hospitals, Homecare, Diagnostic Centers, Ambulatory Surgery Centers, and Others), By Distribution Channel, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Report Overview

Global diabetes treatment devices market size is expected to be worth around USD 17,599 million by 2032 from USD 9,700 million in 2022, growing at a CAGR of 6.3% during the forecast period from 2022 to 2032.

Diabetes refers to a condition in which blood glucose levels rise beyond normal. This is due to a defect of insulin production. Blood glucose is the main source of energy. It can be obtained from the foods that we eat. The blood glucose levels are controlled by insulin, a pancreatic hormone. A defect in insulin synthesis can lead to diabetes. Normal blood glucose levels are between 70 and 100 mg/dL. Diabetes patients may experience an increase of 80-130 mg/dL. Diabetes care devices can be used to monitor the glucose levels of diabetic patients.

A Continuous Glucose Monitor (CGM) is a medical device that continuously monitors the glucose levels of diabetic patients. This wearable technology is especially helpful for people with diabetes as it allows them to control their glucose levels. Many devices can monitor diabetes conditions. These include blood glucose monitor, ketone monitors, and continuous glucose monitors. These devices include smart insulin pens and continuous glucose monitors. To monitor and control glucose levels, glucose monitoring devices can be used. This helps to improve the patient’s overall health.

Key Takeaways

• Market Growth: Expected to reach USD 17,599 million by 2032, growing at a 6.3% CAGR from 2022, due to rising diabetes cases.
• Device Types: Segmented into BGM, Continuous Glucose Monitoring, and Insulin Delivery Devices, offering diverse options.
• Distribution Channels: Include hospital pharmacies, retail pharmacies, online pharmacies, and more, adapting to consumer preferences.
• End-User Dominance: Hospitals held 40.9% of the market in 2021, while homecare is set to grow at a 7.4% CAGR.
• Drivers: Obesity rates contribute to market growth, along with government initiatives, technological innovations, and awareness campaigns.
• Regional Insights: North America dominates, benefiting from established healthcare infrastructure. The Asia-Pacific region is the fastest-growing due to increasing cancer cases.
• Challenges: Painful sensor insertions and device usability challenges impact market expansion.
• Opportunities: Increased funding, government initiatives, and supportive campaigns are anticipated to boost demand in the market.
• Competitive Advantage: Novo Nordisk’s potential dominance in the diabetic treatment devices market.
• Future Trends: The market’s trajectory is shaped by technology advancements, government awareness efforts, and diabetes prevention initiatives.

Device Type Analysis

Based on Device Type, the market for diabetes treatment devices is segmented into BGM Devices (Self-Monitoring Devices, Blood Glucose Meters, Testing Strips, Lancets), Continuous Glucose Monitoring Devices (Sensors, Transmitters, Receiver), Insulin Delivery Devices (Pumps, Disposable pens, Cartridges in Reusable Pens, Syringes, Needles, Diagnostic, Others). The increase in diabetes awareness programs by governments and other organizations is expected to lead to more people using insulin devices.

Distribution Channel Analysis

Online pharmacies can purchase diabetes devices directly from manufacturers. This allows them to offer customers lucrative deals. This segment is driven by a growing awareness of online pharmacies among patients and an increase in public-private funding.

Hospital pharmacies were responsible for high market penetration in recent years. This is due to their high footfall and the availability of products. Inpatient pharmacies and outpatient pharmacies are the two types of pharmacies that can be found within a hospital campus. The hospital’s inpatient pharmacy can only be accessed by authorized personnel.

It is located within the hospital and serves operation rooms, ICUs, special service areas, and other areas. Outpatient pharmacies, on the other hand, are usually located in the hospital’s lobbies or entrances. The outpatient pharmacy has insulin delivery devices and handheld glucose meters. The COVID-19 pandemic had a positive impact on the e-pharmacies industry. Diabetes device sales volumes have increased via this platform.

End-User Analysis

This market was dominated by the hospital segment, which held 40.9% of the total market in 2021.

The demand for this segment is increasing due to the rising number of diabetes patients admitted to hospitals. Three times as likely to be admitted for diabetes than those without it are patients with diabetes. In the last few years, diabetes technology has advanced rapidly. These technologies are designed to improve diabetes care in clinics and hospitals. These technological advances have led to an increase in insulin pump usage in clinics and hospitals. The homecare sector is expected to grow at a 7.4% Compound Annual Growth Rate (CAGR) over the forecast period. This is due to growing awareness of diabetes preventive care.

The demand for insulin pumps in homecare settings is increasing due to increased awareness of diabetes by the government and an easy-to-use interface for insulin pumps. The demand for home care is also increasing due to the aging population. According to the World Health Organization, 80% of all the world’s elderly live in low- or middle-income countries. The total population of 60-year-olds and over is expected to grow to 2 billion by 2050. The demand for insulin pumps in home care settings is increasing because of the above-mentioned factors. This will lead to an exponential growth rate

Key Market Segments

Segmentation of the diabetes treatment devices market can be done by device type, distribution channel, and end-user.

Based on the Device Type

• BGM Devices
• Self-Monitoring Devices
• Blood Glucose Meters
• Testing Strips
• Lancets
• Continuous Glucose Monitoring Devices
• Sensors
• Transmitters
• Receiver
• Insulin Delivery Devices
• Pumps
• Disposable pens
• Cartridges in Reusable Pens
• Syringes
• Needles
• Diagnostic
• Others

Based on Distribution Channel

• Hospital pharmacies
• Retail Pharmacies
• Diabetes Clinics/Centers
• Institutional Sales
• Online Pharmacies
• Others

Based on End-User

• Hospitals
• Homecare
• Diagnostic Centers
• Ambulatory Surgery Centers
• Others

Drivers

Rapid Integration Of Technologically Advanced Digital Diabetes Management Platform

The main factors driving the Diabetes Care Devices Market growth include an increase in diabetes incidence and a shift in urbanization and sedentary lifestyles. The market for diabetic care will be dominated by technological advances in diabetes devices. Blood glucose monitoring devices, however, do not measure glucose levels in the blood. They only give an indication of the range of glucose levels. Market growth is also hindered by the adverse effects of some diabetes care devices. Diabetes Care Devices Market Opportunity will be created by a rising awareness of diabetes monitoring devices and untapped markets in developing countries.

High Amount of Obesity

Obesity is a leading cause of diabetes in the general populace. The WHO records show that around half of the world’s population was overweight or obese. Men are more likely to be obese than women. Diabetes is directly linked to increasing rates of obesity. Accordingly, the market for diabetes devices is growing.

Restraints

Painful sensor insertions and difficulty fitting multiple devices onto small bodies are two factors inhibiting market expansion.

The price of a glucose test device can be high, and painful sensor insertions. Diabetes care devices do not always produce accurate results. Disruptive alerts also, leading data gaps, lost signals, adhesive issues, skin irritation, and improved information generated by difficult-to-carry diabetes care devices.

Opportunity

Increased funding and campaigns in government programs will gain demand for market

The market is also being driven by awareness campaigns and government initiatives. The UK DESMOND education program is an organized, patient education and management program for newly diagnosed type 2 diabetics. Its goal is to help people recognize early health risks. The government has increased funding for healthcare. According to the International Diabetes Federation, diabetes-related healthcare spending is on the rise.

Bigfoot partnered with Abbott to develop the Bigfoot Unity Diabetes Management System. The U.S. FDA approved the collaboration in 2021. This system 2 is the first of its kind and includes smartpen caps that can be used to insert insulin via disposable insulin pens. They integrate with Abbott’s Freestyle Liber 2 technology. Many supportive initiatives and increased awareness are expected to increase diabetes device demand during the forecast period.

Trends

Novo Nordisk is expected to gain a competitive advantage in the diabetic treatment devices market.

Medtronic was awarded a CE Mark in 2021 for its in Pen smart insulin pen, Guardian 4 sensor, and Medtronic Extended Infusion Set in 2021. This set is only available in a few countries. Novo Nordisk is expected to gain a competitive edge in the oral anti-diabetic market with the acquisition of Hemisphere Technologies.

Regional Analysis

North America is the dominant market for diabetes treatment devices due to its well-developed healthcare infrastructure, favorable reimbursement policies, and strong regional leadership.

The Asia-Pacific region is projected to experience the fastest growth in the period 2023-2032. This is due to increasing cancer incidences in the patients such as bladder, liver, bladder, and esophageal, as well as the increased presence of major U.S. manufacturers, technological advances, and increasing foreign investment. This will affect the market’s recent and future trends.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Diabetes treatment devices market is expected to grow during the forecast period due to an increasing prevalence of diabetes. According to the International Diabetes Federation Report 2017, 66.0 million people worldwide have diabetes. This number is expected to rise to 81.0 million by 2045, according to the report. The United Kingdom, France, and Germany are the top five countries with diabetes in Global. It has been shown that North America has more than 29 million diabetes patients. This number is expected to rise to 34 million in 2027. In 2021, the United States alone had more than 26,000,000 diabetes patients. This increases market growth.

Recent Development

• In 2020, Dexcom Corporation Collaborated with DreMed, a medical supplier of equipment which used in hopsitals to enhanced its facilities and this company collaboration improved market appearance of Dexcom as compared to other
• In Nov 2020 announced that Emisphere Technologies, which is a drug delivery technology company, had been acquired by them. Novo Nordisk is expected to gain a competitive advantage in the oral anti-diabetic market with this acquisition.

Listed below are some of the most prominent diabetes treatment devices market industry players.

Market Key Players

• Medtronic plc
• Abbott Laboratories
• Hoffmann-La-Ltd.
• Bayer AG
• Lifescan, Inc.
• B Braun Melsungen AG
• Lifescan, Inc.
• Dexcom Inc.
• Insulet Corporation
• Ypsomed Holdings
• Other key players.

Report Scope